SEC Filing Summary
Filing: Form 10-K for the fiscal year ended December 31, 2017. The supplied filing is for Big Rock Partners Acquisition Corp., not NRX Pharmaceuticals, Inc. The company was incorporated on September 18, 2017 and is a blank check company focused initially on identifying a U.S. senior housing and care target.
Business Context and Reporting Period
- The reporting period covers formation through December 31, 2017; there is no prior comparable operating period because the company was newly formed.
- The company had not commenced substantive commercial operations and had not identified a target business as of December 31, 2017.
- Its initial public offering closed on November 22, 2017, with the underwriters’ over-allotment exercised in full on November 29, 2017.
- The company must complete an initial business combination within 12 months of the IPO closing, subject to up to two three-month extensions, potentially extending the deadline to 18 months.
Financial Position, Results and Liquidity
| Metric | Period-end or period amount |
|---|---|
| Net loss | $105,033 from inception through December 31, 2017 |
| Basic and diluted loss per share | $0.06 loss |
| Operating costs | $134,476 |
| Interest income | $34,183 |
| Unrealized loss on trust-account securities | $4,740 |
| Cash outside the trust account | $449,374 |
| Trust-account securities | $69.03 million |
| Total assets | $69.57 million |
| Current liabilities | $93,171 |
| Common stock subject to possible redemption | $64.47 million |
| Stockholders’ equity | $5.00 million |
| Net cash used in operating activities | $135,807 |
| Net cash used in investing activities | $69.00 million, representing trust-account funding |
| Net cash provided by financing activities | $69.59 million |
| Debt | No long-term debt; related-party IPO-expense loans were repaid |
The company raised $69.0 million from public and private placement units deposited into the trust account. It incurred $2.17 million of IPO-related costs, including $1.725 million of underwriting fees. The company reported no revenue, no operating margin, and no meaningful profitability metrics because it had not yet acquired or operated a business.
Material Changes and Unusual Items
- The principal change during the period was the completion of the IPO, private placement and full over-allotment exercise.
- Public shares subject to potential redemption were classified as temporary equity rather than permanent stockholders’ equity.
- The company issued founder shares, private placement units, representative shares to the underwriter and a unit purchase option, creating potential future dilution.
- In February 2018, the company withdrew $23,135 of trust-account interest to pay franchise tax obligations.
- The company paid its sponsor up to $10,000 per month for office space, utilities and administrative support; $15,000 was incurred through December 31, 2017.
- The auditor issued an unqualified opinion on the financial statements but did not express an opinion on internal control over financial reporting because such an audit was not required for the newly public company.
Outlook, Risks and Contingencies
- Management intends to pursue a business combination, initially emphasizing senior housing and care businesses, but retains broad flexibility to pursue other industries or geographies.
- A target must generally have a fair market value of at least 80% of the trust-account balance and the post-transaction company must obtain a controlling interest.
- If no business combination is completed within the permitted period, the company intends to redeem the public shares and liquidate. Public rights and warrants would expire worthless.
- Each three-month extension requires a $690,000 deposit into the trust account, but the sponsor is not obligated to provide the funding.
- Redemptions, transaction expenses or insufficient outside-trust cash could require additional financing, which may be unavailable or dilutive.
- Claims by creditors, bankruptcy proceedings or failure to enforce the sponsor-affiliated indemnity could reduce distributions below $10 per public share.
- Management and the sponsor have conflicts of interest, including time commitments to other businesses, fiduciary obligations and economic incentives to complete a transaction before the deadline.
- The company expects to complete only one business combination, creating concentration risk in the acquired business.
- There are substantial potential dilution sources from warrants, rights, representative shares, founder shares and the underwriter’s unit purchase option.
Most Important Facts to Verify
- Confirm the correct issuer: the supplied filing identifies Big Rock Partners Acquisition Corp., while the request metadata identifies NRX Pharmaceuticals, Inc.
- Verify the current status of the proposed or completed business combination and whether the company changed its name, ticker or business after this filing.
- Reconcile the trust-account balance, redemption terms, extension payments and any subsequent withdrawals.
- Review all outstanding rights, warrants, founder shares and underwriter options for their potential dilution.
- Assess sponsor indemnification capacity and exceptions that could reduce the amount available to public stockholders.
- Review related-party fees, potential working-capital loans and management conflicts before evaluating transaction economics.